Biocon
Headquarters at Electronic City, Bangalore | |
| Company type | Public |
|---|---|
| BSE: 532523 NSE: BIOCON | |
| ISIN | INE376G01013 |
| Industry | |
| Founded | 1978 |
| Founder | Kiran Mazumdar-Shaw |
| Headquarters | , India |
Key people |
|
| Products |
|
| Revenue | ₹16,470 crore (US$1.9 billion) (2025) |
| ₹4,374 crore (US$520 million) (2025) | |
| ₹1,013 crore (US$120 million) (2025) | |
| Total assets | ₹58,797 crore (US$7.0 billion) (2025) |
| Total equity | ₹27,712 crore (US$3.3 billion) (2025) |
Number of employees | 16,545 (March 2023) |
| Subsidiaries |
|
| Website | www |
| Footnotes / references Financials as of 31 March 2025. | |
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).
Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research and development organization.